Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells

Mihaela Ficu,Dan Niculescu-Duvaz,Mohammed Aljarah,Christopher S. Kershaw,Caroline J. Springer

DOI: https://doi.org/10.26434/chemrxiv-2024-m9px9

2024-08-09

Abstract:The phenotypic effect induced by a Proteolysis-Targeting Chimera (PROTAC) can depend on several factors, including the E3 ligase recruited. For the discovery of a first-in-class PROTAC for a target of interest, the E3 ligases commonly hijacked remain the Von Hippel-Lindau (VHL) and Cereblon (CRBN) since potent and accessible ligands are readily available to recruit them. Mouse double minute 2 (MDM2) E3 ligase stands out because it regulates p53 levels to maintain cellular homeostasis. However, the synthesis of the most potent MDM2 ligands remains very complex. Here we report the discovery of novel MDM2-recruiting PROTACs incorporating rac-Nutlin-3 as a ligand with an easier synthetic tractability, further demonstrating its potential in this technology. The most promising degrader, PROTAC 3, showed preferential degradation of the BRD4 short isoform and c-Myc compared with MZ1, a validated VHL-based PROTAC.

Chemistry

What problem does this paper attempt to address?

The main objective of this paper is to develop a novel PROTAC (Proteolysis-Targeting Chimera) molecule for the targeted degradation of BRD4 protein in pancreatic cancer cells. Specifically, the research team designed and synthesized novel PROTAC molecules targeting the MDM2 (Mouse Double Minute 2) E3 ubiquitin ligase and evaluated the efficacy of these molecules in the pancreatic cancer cell line MIA PaCa-2. Key contributions of the paper include: - Development of a series of MDM2-based PROTAC molecules that incorporate rac-Nutlin-3 as the MDM2 ligand, which are easier to synthesize. - Discovery of a molecule named PROTAC 3, which can effectively degrade the short form of BRD4 protein (BRD4 S) as well as c-Myc protein, showing better performance compared to the known VHL (Von Hippel-Lindau)-based PROTAC molecule MZ1. - Experimental validation of the mechanism of action of PROTAC 3, demonstrating that its effect depends on its binding to BRD4 and that it exhibits stronger degradation effects at higher concentrations. In summary, this study aims to explore the potential of using MDM2 E3 ubiquitin ligase for PROTAC molecule design and demonstrates the potential of this strategy in the treatment of pancreatic cancer.

Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells

PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: an Updated Perspective.

Homo-PROTAC Mediated Suicide of MDM2 to Treat Non-Small Cell Lung Cancer

PROTACs: A novel strategy for cancer therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Clinical considerations for the design of PROTACs in cancer

Novel PROTAC probes targeting KDM3 degradation to eliminate colorectal cancer stem cells through inhibition of Wnt/β-catenin signaling

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Discovery of an Activatable Near-Infrared Fluorescent and Theranostic PROTAC for Tumor-Targeted Detecting and Degrading of BRD4

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression

PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models

Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy